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We investigated the emergence and evolution of drug-
resistant tuberculosis (TB) in an HIV co-infected population 
at a South African gold mine with a well-functioning TB con-
trol program. Of 128 patients with drug-resistant TB diag-
nosed during January 2003–November 2005, a total of 77 
had multidrug-resistant (MDR) TB, 26 had pre–extensively 
drug-resistant TB (XDR TB), and 5 had XDR TB. Genotyp-
ing suggested ongoing transmission of drug-resistant TB, 
and contact tracing among case-patients in the largest clus-
ter demonstrated multiple possible points of contact. Phylo-
genetic analysis demonstrated stepwise evolution of drug 
resistance, despite stringent treatment adherence. These 
ﬁ  ndings suggested that existing TB control measures were 
inadequate to control the spread of drug-resistant TB in this 
HIV co-infected population. Diagnosis delay and inappro-
priate therapy facilitated disease transmission and drug-
resistance. These data call for improved infection control 
measures, implementation of rapid diagnostics, enhanced 
active screening strategies, and pharmacokinetic studies to 
determine optimal dosages and treatment regimens.
T
he emergence of drug-resistant tuberculosis (TB) is 
often attributed to the failure to implement proper TB 
control programs and correctly manage TB cases (1,2). 
Consequently, >450,000 multidrug-resistant (MDR) TB 
cases (resistant to at least isoniazid and rifampin) are es-
timated to occur globally each year, of which 1%–2% oc-
cur in South Africa (3,4). A recent survey conducted by 
the World Health Organization (WHO) and the Centers for 
Disease Control and Prevention (Atlanta, Georgia, USA) 
estimated that 7% of MDR TB samples were also exten-
sively drug-resistant (XDR) TB (5), i.e., resistant to isoni-
azid and rifampin and to at least 1 representative of each 
class of the most effective second-line drugs (i.e., ﬂ  uoro-
quinolones and the injectable drugs kanamycin, amika-
cin, or capreomycin). Concern over XDR TB was further 
heightened with the identiﬁ  cation in 2006 of an XDR TB 
outbreak involving 53 cases in South Africa (6). This out-
break had an exceptionally high proportion of deaths among 
HIV co-infected case-patients and demonstrated the need 
for improved basic TB control measures (7) and enhanced 
infection control. Subsequently, those involved in investi-
gating the outbreak suggested that, in the absence of drug-
susceptibility testing (DST), the evolution of MDR TB and 
XDR TB was inevitable (8). A recent study in Uzbekistan 
showed the emergence of XDR TB while patients were 
being treated for MDR TB, which suggests that treatment 
regimens should be optimized and strategies developed for 
administering these regimens safely and effectively (9).
In 1999, WHO put forward the directly observed treat-
ment short course (DOTS)–plus strategy, which proposed 
that the diagnosis and treatment of MDR TB could comple-
ment a well-functioning DOTS program and thereby con-
Emergence of Increased Resistance 
and Extensively Drug-Resistant 
Tuberculosis Despite Treatment 
Adherence, South Africa 
Alistair D. Calver,1 Alecia A. Falmer,1 Megan Murray, Odelia J. Strauss, Elizabeth M. Streicher, 
Madelene Hanekom, Thelma Liversage, Mothusi Masibi, Paul D. van Helden, Robin M. Warren, 
and Thomas C. Victor
RESEARCH
264  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 2, February 2010
1These authors contributed equally to this article.
Author afﬁ  liations: West Vaal Hospital, Orkney, South Africa (A.D. 
Calver, T. Liversage, M. Masibi); Stellenbosch University, Tyger-
berg, South Africa (A.A. Falmer, O.J. Strauss, E.M. Streicher, M. 
Hanekom, P.D. van Helden, R.M. Warren, T.C. Victor); and Harvard 
School of Public Health, Boston, Massachusetts, USA (M. Murray) 
DOI: 10.3201/eid02l0.090968 XDR TB and Treatment Adherence
trol the emergence and spread of TB (10). These strategies 
have been implemented since 2000 by the health service 
at a gold mine in the North West Province in South Af-
rica. Furthermore, a policy of biannual chest radiographic 
screening has been instituted, which contributes to the early 
identiﬁ  cation of patients with active pulmonary TB (PTB). 
Using these rigorous case-ﬁ  nding and treatment strategies, 
the program has been able to achieve successful treatment 
outcomes in >85% of new sputum smear–positive TB cases 
since 2001 and an average of 77.2% successful for retreat-
ment of smear-positive cases (A.D. Calver, unpub. data). 
Despite this success, the incidence of drug-susceptible TB 
has continued to rise, an increase that reﬂ  ects both the ris-
ing HIV prevalence in this community and the occupation-
al risks speciﬁ  c to the mine setting such as silicosis, con-
gregate living, and working conditions. In 2003, a marked 
increase (2.4×) in the number of case-patients with DR TB 
was noted at this gold mine. We investigated this outbreak 
using a molecular epidemiologic approach and  clinical and 
epidemiologic data to identify inadequacies in the imple-
mented DOTS-plus strategy that lead to the emergence of 
pre–XDR TB (MDR TB with resistance to either kanamy-
cin or oﬂ  oxacin [11]) and XDR TB.
Materials and Methods
Study Population
This study was conducted at a gold mine in South Af-
rica, January 2003–November 2005. Any employee with 
a new lesion detected on biannual occupational health 
chest radiographic screening is referred to the hospital. 
Similarly, all persons with self-reported suspected TB and 
unexplained weight loss, unexplained persistent cough for 
>2 weeks, and unexplained night sweats are also referred 
for TB investigation. A bacteriologic diagnosis of PTB 
was made by auramine-O ﬂ  uorescent stain microscopy 
of 4 concentrated sputum smears and 2 TB cultures us-
ing Mycobacterial Growth Indicator Tube (MGIT) (BD 
Diagnostic Systems, Franklin Lakes, NJ, USA). Patients 
who had negative smear and culture results and chest 
radiographic results suggestive of PTB were monitored 
with repeat sputum smears. They were treated for TB 
only if other causes for the lesion could not be found and 
the patients’ symptoms and radiographic results deterio-
rated. DST for isoniazid and rifampin was performed on 
all positive Mycobacterium tuberculosis cultures by using 
MGIT. Time from seeking treatment until diagnosis of 
drug resistance (isoniazid and rifampin) ranged from 21 
to 112 days. Second-line DST was done for ethambutol, 
oﬂ  oxacin, and kanamycin in MGIT 960 media containing 
5 μg/mL, 2 μg/mL, and 4 μg/mL, respectively. Pyrazi-
namide DST was carried out according to the BACTEC 
manual (BD Diagnostic Systems) (12). 
Patients with bacteriologically conﬁ   rmed cases of 
TB were treated according to WHO/International Union 
Against Tuberculosis and Lung Disease guidelines. They 
were treated within the hospital to limit community trans-
mission until sputum smears were negative for 2 consecu-
tive specimens collected on separate days (checked week-
ly). Thereafter, patients received supervised outpatient 
treatment, and adherence was monitored by observing the 
patient receive and swallow the issued daily doses. Adher-
ence rates were reported to the mine healthcare service 
management and ranged from 95% to 98%.
Patients with a diagnosis of MDR TB were hospital-
ized and treated based on current DOTS-plus guidelines 
from the South African National TB control program. 
Treatment regimens included at least 4 drugs and were 
based previous treatment history and DST. Injectable drugs 
were stopped when sputum cultures were negative for at 
least 2 successive months or when side effects necessitated 
discontinuance. Once sputum cultures had been negative 
for at least 3 successive months, patients were discharged 
to outpatient treatment. Oral medication was continued for 
at least 12 months after the ﬁ  rst negative culture, with a 
minimum total duration of 18 months. An outcome of cure 
was assigned to patients with MDR TB or XDR TB if they 
maintained culture conversion and completed a full course 
of treatment for >18 months. Transferred out was deﬁ  ned 
as a patient who was transferred to another healthcare facil-
ity for further TB treatment.
Infection Control
Patients with positive smear cultures were admitted to 
a TB ward, which is equipped with UV lights and is sepa-
rated from the rest of the hospital wards by a 100-m cross-
ventilated corridor. The windows in the TB ward are open 
throughout the year, creating good natural cross-ventila-
tion. Although patients were advised to avoid close contact 
with patients from other wards, patients were not conﬁ  ned 
to this ward, and some contact may have occurred within 
the hospital grounds. In addition, some patients were diag-
nosed with PTB while they were hospitalized and were be-
ing assessed for other conditions. Such patients were sub-
sequently transferred to the TB ward. Before 2004, patients 
with DR TB were hospitalized in a miniward within the TB 
ward used for patients with drug-susceptible disease. How-
ever, in response to the increase in the number of MDR TB 
patients, a separate MDR TB ward was opened in 2004. 
This ward is separated from the rest of the hospital by elec-
tronically locked doors for restricted entry and exit, is ﬁ  tted 
with ceiling mounted UV air sterilizing units, and patients 
leaving the ward are ﬁ  tted with a PF95 mask. However, pa-
tients are kept on the general TB ward until drug-resistant 
disease is conﬁ  rmed, at which point they are transferred to 
the MDR TB ward.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 2, February 2010  265 RESEARCH
Participant Enrollment
All mine employees and dependents with drug-resis-
tant TB diagnosed during January 2003–November 2005 
were included in this study (average number of persons 
covered per year: 28,943 in 2003, 25,541 in 2004, and 
21,790 in 2005). Clinical and demographic data were col-
lected retrospectively and included the following: age, sex, 
site of disease (PTB or extrapulmonary TB), sputum smear 
results, treatment category (new or retreatment cases), TB 
outcome, HIV status (despite extensive patient education 
and counseling, there are reluctance and denial issues relat-
ing to HIV testing), antiretroviral treatment (ART), place 
of residence within the mine area, and dates and locations 
of hospital stays. This study was approved by the ethics 
committee (internal review board) of Stellenbosch Univer-
sity, Tygerberg, South Africa.
Genotyping
Drug-resistant  M. tuberculosis isolates were geno-
typed by insertion sequence (IS) 6110 restriction frag-
ment-length polymorphism (RFLP) (13), spoligotyp-
ing (14), and mycobacterial interspersed repetitive unit 
(MIRU) typing (12-loci format) (15). The katG, rpoB, 
pncA, embB, and gyrA genes of the M. tuberculosis isolates 
were sequenced by using the ABI PRISM DNA sequencer 
(Applied Biosystems, Foster City, CA, USA) to identify 
nonsynonymous single nucleotide polymorphisms confer-
ring isoniazid, rifampin, pyrazinamide, ethambutol, and 
oﬂ  oxacin resistance, respectively (16). Strains that share 
an identical genotype (spoligotype, IS6110 RFLP, and 
MIRU type for low copy-number strains) were classiﬁ  ed 
as clustered; clustered strains were considered to be part 
of an ongoing chain of transmission. Isolates with unique 
strain genotypes from new cases-patients with drug-re-
sistant TB were considered to have primary resistance, 
whereas isolates with unique strain genotypes from pa-
tients undergoing retreatment were thought to have either 
acquired resistance during therapy or to be a reactivated a 
drug-resistant strain (17).
To elucidate the molecular evolution of drug resis-
tance within a transmission chain, we conducted a phylo-
genetic analysis using DNA sequence data from isolates 
from the single large cluster detected through genotyping. 
We used 2 distinct algorithms: 1) the heuristic parsimony 
algorithm, and 2) the neighbor-joining distance algorithm 
in conjunction with sampling the original dataset with re-
placement to construct a series of 1,000 bootstrap repli-
cates of the same size as the original dataset (PAUP 4.0* 
software version 4; Sinauer Associates, Sunderland, MA, 
USA) (18). A consensus tree was generated by using the 
program CONTREE (PAUP 4.0*) in combination with 
the majority rule formula.
Contact Tracing
Hospital and employment records were reviewed to 
identify potential sites of contact between patients in the 
largest cluster. We considered patients to have been ex-
posed to MDR TB within the hospital setting if they been 
previously admitted to the hospital before their admission 
for diagnosis with MDR TB, during which time a patient 
with active MDR TB of an identical genotype had also bee 
also hospitalized. Patients were considered to have had 
work contact if they had worked the same mine shaft as a 
person with an MDR TB diagnosis, and to have had resi-
dential contact if they lived in the same building or group 
of buildings before MDR TB diagnosis.
Statistical Analysis
For univariate analyses of clustering, we used logistic 
regression to estimate odds ratios (ORs) and 95% conﬁ  -
dence intervals (CIs). We calculated p values by using the 
Mantel-Haenszel χ2 method or Fisher exact test. Statistical 
tests were 2-sided. We used a multivariate logistic regres-
sion model to control for possible confounders. We also 
used a logistic regression model to estimate the OR of death 
among patients infected with clustered strains. Analyses 
were performed with STATA software version 9.0 (Stata-
Corp LP, College Station, TX, USA) and SAS version 9.1 
(SAS Institute, Cary, NC, USA).
Results
During the study period, 3,003 patients with TB were 
notiﬁ  ed; 1,443 (48%) had new PTB cases, 755 (25%) were 
being re-treated for PTB, and 805 (27%) patients had ex-
trapulmonary TB. Of these case-patients, 70% sought treat-
ment on their own at healthcare clinics or hospital with 
symptoms, while the remaining 30% were identiﬁ  ed by 
active screening. Successful treatment (cure or treatment 
completed) was achieved in 86.5% of all TB case-patients 
during the study. Less than 2% of TB case-patients default-
ed or had an unsuccessful treatment outcome, and 12% of 
TB case-patients died as a result of TB or other causes. One 
hundred twenty-eight (4.3%) TB case-patients had drug-
resistant TB; of those, 13 (10.2%) were diagnosed with iso-
niazid-resistant TB, 7 (5.6%) with poly–drug-resistant TB, 
and 108 (84.4%) with MDR TB. Among isolates identiﬁ  ed 
as MDR TB, 26 were pre–XDR TB and 5 were XDR TB. 
Table 1 summarizes demographic and clinical charac-
teristics of the cohort of 128 patients with drug-resistant 
TB. All of the employees had worked at the mine for at least 
6 months (median 15.0 years, range 0.5–27 years) and had 
passed a preemployment physical examination that ruled 
out active TB. Among those who were HIV seropositive, 
60 (70.4%) had smear-positive TB and 52 (62.0%) had a 
CD4 count of <200 cells/mm3 (median 74 cells/mm3). Fif-
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ty-six (66.6%) of those seropositive for HIV were receiving 
HIV education from the wellness HIV clinic; 7 (8.3%) had 
initiated ART before being diagnosed with drug-resistant 
TB, and 22 (26.2%) had initiated ART after being diag-
nosed with MDR TB. Among those who started ART after 
being diagnosed with drug-resistant TB, the median time 
from diagnosis to initiation of ART was 172 days (range 
41–1,425 days).
Outcomes were generally poor, with only 31.3% com-
pleting treatment with conﬁ  rmed bacteriologic cure. Forty-
ﬁ  ve (35.2%) patients died; 7 (15.6%) of those who died 
did not have a conﬁ  rmed TB diagnosis at time of death, 12 
(26.7%) had been diagnosed with TB but were receiving 
standard therapy at the time of death, and 26 (57.8%) case-
patients who were  receiving MDR TB treatment died. Of 
note, >50% of the deaths were due to other AIDS-related 
conditions. Among those who died, median time to death 
from beginning of treatment was 5 months (range 1–24 
months). 
Combined genotype analysis of isolates from 124 of 
the 128 case-patients identiﬁ  ed 61 distinct drug-resistant 
genotypes (online Appendix Figure, www.cdc.gov/EID/
content/16/2/264-appF.htm). Fifty isolates were unique 
and 74 were clustered. Among the 11 clusters, the clus-
ter size ranged from 2 to 42. We estimate that at least 63 
(85.1%) of the 74 clustered isolates had primary drug resis-
tance, assuming that each cluster was initiated by an isolate 
that acquired drug resistance (19). Among the 50 unique 
genotypes, 25 (50%) were cultured from new case-patients, 
which suggests primary drug resistance. Accordingly, we 
suggest that 71% of drug-resistant TB cases resulted from 
transmission of preexisting drug resistant strain.
Clustering was more frequent among case-patients 
with MDR TB than among those with monoresistant or 
polyresistant strains (unadjusted OR 14.20, p = 0.001; ad-
justed OR 14.13, p = 0.002) (Table 2). When we compared 
clustering among pre–XDR TB and XDR TB isolates and 
those with monoresistance or polyresistance, we found 
that these highly resistant strains were also more likely to 
be in a cluster than those with less resistance (unadjusted 
OR 27.42, p<0.001). Twenty (76.9%) of the pre–XDR 
TB strains and 4 (80%) of the XDR TB strains clustered 
with circulating MDR TB strains. Table 2 illustrates that 
additional risk factors for clustering were not identiﬁ  ed in 
either the univariate or multivariate analysis, although pa-
tients in clusters were more likely to die than those whose 
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Table 1. Characteristics of mine workers with drug-resistant TB diagnosed January 2003–January 2005, South Africa* 
Characteristic
No. (%) HIV+ 
workers  
No. (%) HIV– 
workers 
No. (%) workers with 
unknown HIV status 
Total no. (%) 
workers  
Total 84 7 37 128
Age (average)  43 43 42 43
Sex 
  M  82 (97.6)  7 (100)  35 (94.6)  124 (96.9) 
  F  2 (2.4)  0 2 (5.4)  4 (3.1) 
Case definition 
  New  38 (45.2)  0 18 (48.6)  56 (43.7) 
  Retreatment†  46 (54.8)  7 (100)  19 (51.4)  72 (56.3) 
Sputum smear‡ 
  Positive  60 (70.4)  4 (57.1)  31 (83.8)  95 (74.2) 
  Negative  24 (28.6)  3 (42.9)  5 (13.5)  32 (25) 
Drug-resistance phenotype 
  Isoniazid (mono) resistant  8 (9.5)  1 (14.3)  4 (10.8)  13 (10.1) 
  Poly resistant  4 (4.8)  0 3 (8.1)  7 (5.5) 
  MDR  72 (85.7)  6 (85.7)  30 (81.1)  108 (84.4) 
  Pre–XDR  22 (26.2)  3 (42.9)  1 (2.7)  26 (20.3) 
  XDR  2 (2.4)  1 (14.3)  2 (5.4)  5 (3.9) 
Outcome
  Treatment completed or bacteriologic cure  26 (30.1)  3 (42.9)  11 (29.7)  40 (31.3) 
  Failed  1 (1.3)  0 0 1 (0.8) 
  Died  31(36.9)  2 (28.6)  12 (32.4)  45 (35.2) 
  Transferred out  20 (23.8)  2 (28.6)  10 (27.0))  32 (25.0) 
  Lost to treatment§  6 (7.1)  0 4 (10.8)  10 (7.8) 
CD4 cell count, cells/mm
3¶
  <200  52 (62)  ND 5 (13.5)  57 (44.5) 
  >200  18 (21.4)  2 (28.6)  ND 20 (15.6) 
*TB, tuberculosis; MDR, multidrug-resistant; XDR, extensively drug-resistant; ND, not determined. 
†All prior TB episodes were treated at the mine. 
‡1 sputum smear result missing. 
§One had monoresistant TB and 9 had MDR TB. 
¶CD4 counts available for 77 patients only. RESEARCH
isolates were not clustered (unadjusted OR 2.28, p = 0.04; 
adjusted OR 4.76, p = 0.007). Of note, 59% of clustered 
case-patients had a documented previous episode of TB, 
which suggests reinfection with a circulating strain (Table 
2). Although higher CD4 counts were associated with less 
clustering (unadjusted OR 0.49, p = 0.19; adjusted OR 0.51, 
p = 0.28), this association did not reach signiﬁ  cance. 
Figure 1 demonstrates that most patients in the largest 
cluster had multiple different types of contact; 32 (76.2%) 
had a non–MDR TB hospitalization at the same time anoth-
er patient in the cluster was admitted for MDR TB. Thirty-
nine (92.9%) patients worked in a shaft in which another 
MDR TB patient in the cluster had worked, and 36 (85.7%) 
of the patients resided in the same residential unit where 
another MDR TB patient had lived.
Phylogenetic reconstructions of the isolates included 
in the largest identiﬁ  ed a single genetically distinct pro-
genitor MDR TB strain (Figure 2). This strain acquired 
resistance to pyraziamide on 2 separate occasions and 
both of these strains were subsequently transmitted. 
Thereafter, ethambutol resistance evolved independently 
in several different cases. Sequencing of the gyrA gene 
showed that oﬂ  oxacin resistance subsequently evolved on 
6 separate occasions, resulting in 15 cases of pre–XDR 
TB. One of these pre–XDR TB strains then evolved to 
XDR TB and caused disease in a single patient (patient 
27). An additional XDR TB strain evolved independently 
(lacking gyrA mutations) (patient 41) and subsequently 
spread to a contact (patient 141).
Discussion 
Using a combination of clinical, epidemiologic, and 
molecular data, we showed that drug-resistance was pri-
marily transmitted in this mine setting, thereby suggesting 
that the current TB control program was largely able to 
prevent the acquisition of drug-resistance to at least the 
ﬁ  rst-line anti-TB drugs could not prevent the transmission 
of preexisting MDR TB in this highly vulnerable popula-
tion. Similar ﬁ  ndings have been reported for community 
based settings in South Africa (21,22). Our results also 
demonstrated that a large proportion of patients who had a 
previous documented episode of TB were reinfected with 
a circulating MDR TB strain. These ﬁ  ndings are consis-
tent with those from another recent study which showed 
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Table 2. Patient risk factors for having clustered TB isolates, January 2003–January 2005, South Africa*† 
Cluster status 
Category  Unique, n = 50  Clustered, n = 74  Univariate OR  p value  Multivariate OR  p value 
Treatment history 
 Re-treatment  25 44
  New  case  25 30 1.47 0.29 0.69 0.50
Sex 
 M  49 71
 F  1 3 1.27 0.52 NI
Age, y 
 <45  33 51
>45 17 23 0.87 0.73 NI
HIV status 
 Negative  4 3
 Positive  29 53 2.43 0.26 2.33 0.33
Sputum smear 
 Negative  14 19
 Positive  36 55 1.12 0.77 NC
MDR TB 
  Mono or poly resistant  16 2
  INH and RIF resistant  34 72 14.2 0.001 14.13 0.002
MDR plus 
  Mono or poly resistant  16 2
 Pre–XDR  TB/XDR  TB  7 24 27.42 <0.001 NC
Died
 No  38 42
 Yes  12 32 2.28 0.04 4.76‡ 0.007‡
CD4 count, cells/mm
3
 <200  15 42
 >200  8 11 0.49 0.19 0.51§ 0.28
*TB, tuberculosis; OR, odds ratio; NI, variables not included in final logistic regression model based on model selection criteria; NC, variables a priori not 
considered in logistic regression model; MDR, multidrug-resistant; XDR, extensively drug-resistant; INH, isoniazid; RIF, rifampin. 
†Logistic regression performed on 71 observations for which HIV and CD4 available, model adjusted for treatment history, HIV, CD4, and MDR. 
‡Logistic regression on probability of death given clustering, adjusting for HIV, MDR-plus, and age. 
§CD4 counts available for 77 patients only.  XDR TB and Treatment Adherence
that patients in China with drug-resistant TB who had 
previously received treatment were frequently infected 
with a clustered (i.e., recently transmitted) strain (23). 
In previous work, we demonstrated that a prior episode 
of TB may increase the risk of a subsequent episode of 
disease through reinfection, even in a population with a 
low HIV prevalence (24). This heightened susceptibil-
ity may be especially severe in HIV co-infected patients, 
given previous concerns that TB may accelerate immune 
suppression (25).
In this study, a large proportion of the HIV-infected 
TB patients had smear-positive TB, despite the fact that 
many had CD4 counts <200 cells/mm3. These data are 
consistent with previous ﬁ  ndings that suggest that 35% of 
TB cases in HIV-infected persons are smear negative (26). 
Most notably, this ﬁ  nding demonstrated that in this high 
risk environment, HIV co-infected patients can transmit 
TB to close and susceptible contacts, even in the setting of 
a vigorous TB control program. Of note, we found that ac-
tive case ﬁ  nding by biannual chest radiographic screening 
identiﬁ  ed only 30% of TB cases
Our phylogenetic reconstruction of the largest cluster 
of cases demonstrated sequential acquisition of resistance-
causing mutations. We believe that the evolution of resis-
tance to ethambutol and pyrazinamide represents the further 
ampliﬁ  cation of drug resistance in the context of patients 
with undiagnosed MDR TB initially being given standard 
therapy (27). An MDR TB case-patient with a strain resis-
tant to isoniazid, rifampin, ethambutol, and pyrazinamide 
could then spread disease to persons who were co-hospi-
talized for drug-susceptible TB or illnesses other than TB. 
Disease may develop in these persons, and they can then 
spread MDR TB to their contacts at their place of work or 
residence, thereby unintentionally perpetuating the drug-
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Figure 1. Venn diagram of number of potential contacts by type 
among patients in the largest multidrug-resistant tuberculosis 
(MDR TB) cluster, South Africa, 2003–2005. Each circle represents 
potential places of contact: shaft, mine shaft (work); residence, 
place of residence; hospital, hospitalization at the same time as 
another MDR TB case-patient.
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Figure 2. Phylogenetic history of the largest multidrug-resistant 
tuberculosis (MDR TB) cluster, South Africa, 2003–2005. Genetic 
data from isolates from 40 of the 42 case-patients were analyzed. 
The phylogenetic tree was constructed by using the neighbor 
joining algorithm (PAUP 4.0*; Sinauer Associates, Sunderland, MA, 
USA) and was rooted to the H37Rv wild-type DNA sequence (ANC) 
(20). The gene and the codon conferring resistance are indicated 
at the internal node where they occurred. Bootstrap values are 
shown in brackets at the internal nodes. The sequential evolution 
of resistance to HRZE and Ofx is indicated. The date of MDR TB 
diagnosis follows each case number. The 3 XDR TB cases are 
indicated in boldface. H, isoniazid, R, rifampin, E, ethambutol, Z, 
pyrazinamide, Ofx, oﬂ  oxacin. RESEARCH
resistant TB outbreak. We believe that this observation is 
not unique to this setting (12,28–32).
Our phylogenetic analysis also indicated that oﬂ  oxacin 
resistance emerged on many occasions after acquisition of 
resistance to ﬁ  rst-line drugs. Although these data suggest 
that treatment of MDR TB patients with second-line drugs 
resulted in the evolution of oﬂ  oxacin resistance, the mecha-
nisms by which patients acquired this resistance, despite 
excellent adherence to MDR TB treatment, remain unclear. 
This stresses the need for pharmacokinetic studies to opti-
mize dosages and treatment regimens for MDR TB in HIV 
co-infected patients and HIV uninfected patients.
In conclusion, we recommend that DOTS and DOTS-
Plus TB control programs (33) should be integrated with 
well functioning HIV management programs to ensure that 
ARVs are widely administered to limit susceptibility to TB 
disease. Furthermore, additional intervention measures are 
required to identify infectious cases. Such measures should 
include, increasing public awareness of TB symptoms, ac-
tive screening of all patients making contact with the health 
care services and more aggressive case ﬁ  nding. The high 
proportion of smear positive cases with drug-resistant TB 
suggests that more frequent sputum smear examinations 
may allow for the early identiﬁ  cation these infectious cas-
es. In addition, more frequent culture based diagnosis may 
identify cases before they become infectious. This study 
also emphasizes the importance of the development and 
implementation of rapid DST diagnostics to minimize the 
delay in detecting MDR TB and the risk of inadvertently 
placing the patient on a regimen that could lead to the am-
pliﬁ  cation of drug-resistance (34). Rapid DST diagnostics 
may help to prevent nosocomial spread of MDR TB since 
patients could be rapidly identiﬁ  ed and isolated from others 
(26). Our ﬁ  nding that a large proportion of patients in the 
largest cluster were hospitalized at the same time, raises 
the possibility that transmission was nosocomial. This may 
be curtailed by more rigorous infection control measures. 
We recommend that adequate infection control measures 
should be implemented in all hospital departments and 
gathering places to prevent nosocomial infections.
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